Pharmaceuticals
Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Initiating Phase 1b randomized clinical trial with initial results expected in late 2021 Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants CINCINNATI, March 26, 2021 /PRNewswire/ --...
2021-03-26 16:00
3602
Ascentage Pharma Announces Publication of Preclinical Data in Nature Immunology Showing Enhanced T-Cell-Mediated Antitumor Immunity Induced by Its MDM2-p53 Inhibitor APG-115
SUZHOU, China and ROCKVILLE, Md., March 26, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the peer-reviewed publicati...
2021-03-26 08:38
3245
Antengene Announces Financial Results for Full Year 2020
SHANGHAI and HONG KONG, March 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" or "the company", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in h...
2021-03-26 08:00
4450
Chime Biologics Announced the Completion of US$190 Million Series A+ Financing to Accelerate Capacity Expansion
WUHAN, China, March 26, 2021 /PRNewswire/ -- Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment ofUS$190 million investment from institutional investors, and over $100 million investment has already been closed today. This round of fin...
2021-03-26 08:00
5939
Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round
CINCINNATI, March 26, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at$4 million. Investments ...
2021-03-26 05:19
3672
Antengene Appoints Kevin Lynch as Chief Medical Officer
SHANGHAI, China and MELBOURNE, Australia, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in ...
2021-03-25 23:26
4572
Antengene Appoints Bo Shan as Chief Scientific Officer
SHANGHAI, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announc...
2021-03-25 22:36
5989
CStone Pharmaceuticals Reports Financial Results and Business Highlights for Full-year 2020
SUZHOU, China, March 25, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today reported financial results and business highlights for the f...
2021-03-25 22:03
5120
BioNTech Chairman Helmut Jeggle joins the Board of IQM Quantum Computers
MUNICH, March 25, 2021 /PRNewswire/ -- IQM Quantum Computers
2021-03-25 18:29
3555
AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine
AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou,...
2021-03-25 17:00
3560
Nippon Express Obtains IATA CEIV Pharma Certification for Temperature-controlled Facility near Narita Airport
TOKYO, March 25, 2021 /PRNewswire/ -- Nippon Express Co., Ltd. has obtained IATA CEIV Pharma (*) pharmaceutical transport quality certification for its Narita Temperature-Controlled Hub (NTCH) and for transport operations between NTCH and Narita Airport, effectiveMarch 15. This is the second pha...
2021-03-25 15:00
2973
Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar
TAIPEI, March 24, 2021 /PRNewswire/ -- In a press conference today, EirGenix, Inc. (6589.TT) announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint. E...
2021-03-24 23:27
4908
Ascentage Pharma's First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation
SUZHOU, China and ROCKVILLE, Md., March 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Ev...
2021-03-24 19:07
2731
Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson's disease with the US FDA
HONG KONG, March 23, 2021 /PRNewswire/ -- Forest Hills Partners Hong Kong Limited (also known as Forest Hills Lab) is ready to file an Investigative New Drug (IND) application with the US FDA inApril 2021 to assess tolerability and efficacy with one of its drug candidates, namely FHL-301 in a pha...
2021-03-24 12:25
5849
CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients
* GAVRETO has been approved for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy * GAVRETO is the first approved selective RET inhibitor in China and first approved precision therapy for CStone SUZHOU,...
2021-03-24 10:46
5942
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention. BAGSVÆRD, Denmark, March 24, 2021 /PRNewswire/ -- New results from the STEP phase 3a clinical trial p...
2021-03-24 04:41
1684
Pharma Industry to Spend $4.5 Billion on Digital Transformation by 2030
While the creation, manufacture, and supply of COVID vaccines are grabbing attention, behind the scenes, pharma manufacturers are digitizing at pace LONDON, March 23, 2021 /PRNewswire/ -- Pharma 4.0 concepts are taking hold in pharmaceutical manufacturing. The industry's unique characteristics ar...
2021-03-23 16:00
1828
Diluent or Immuno-Reagent solutions for your diagnostic testing kits (Covid, Flu, etc.)
PARIS, March 23, 2021 /PRNewswire/ -- Unither Pharmaceuticals, the
Blow-Fill-Seal (BFS) worldwide leader, provides diagnostic companies with
capacity solutions and innovative technologies for their testing kits (Covid,
Flu, etc.).
2021-03-23 15:04
2979
Taiko Pharmaceutical Officially Launches "Cleverin" in Mexico, Top Made-in-Japan Brand for Removing Viruses/Bacteria, Deodorization
OSAKA, Japan, March 23, 2021 /PRNewswire/ -- Together with a local distribution partner, Torishi S.A. de C.V., Taiko Pharmaceutical Co., Ltd. (hereinafter Taiko), based inOsaka, Japan, has announced the launch of "Cleverin," a top made-in-Japan brand (*1) among products for removing viruses/bacte...
2021-03-23 14:00
4442
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Hungary
* Marks vaccine's first approval by an European Union member state, following Mexico, Pakistan and China * Continues to boost production capacity to meet increasing demand * Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions * 95.47% effectiv...
2021-03-23 00:43
4450
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 326 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
8004